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Abstract
In humans, gain-of-function mutations of the calcium-sensing receptor (CASR) gene are the cause of autosomal dominant
hypocalcemia or type 5 Bartter syndrome characterized by an abnormality of calcium metabolism with low parathyroid
hormone levels and excessive renal calcium excretion. Functional characterization of CaSR activating variants has been so
far limited at demonstrating an increased sensitivity to external calcium leading to lower Ca-EC50. Here we combine high
resolution fluorescence based techniques and provide evidence that for the efficiency of calcium signaling system, cells
expressing gain-of-function variants of CaSR monitor cytosolic and ER calcium levels increasing the expression of the Sarco-
Endoplasmic Reticulum Calcium-ATPase (SERCA) and reducing expression of Plasma Membrane Calcium-ATPase (PMCA).
Wild-type CaSR (hCaSR-wt) and its gain-of-function (hCaSR-R990G; hCaSR-N124K) variants were transiently transfected in
HEK-293 cells. Basal intracellular calcium concentration was significantly lower in cells expressing hCaSR-wt and its gain of
function variants compared to mock. In line, FRET studies using the D1ER probe, which detects [Ca2+]ER directly,
demonstrated significantly higher calcium accumulation in cells expressing the gain of function CaSR variants compared to
hCaSR-wt. Consistently, cells expressing activating CaSR variants showed a significant increase in SERCA activity and
expression and a reduced PMCA expression. This combined parallel regulation in protein expression increases the ER to
cytosol calcium gradient explaining the higher sensitivity of CaSR gain-of-function variants to external calcium. This control
principle provides a general explanation of how cells reliably connect (and exacerbate) receptor inputs to cell function.
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Introduction
The extracellular calcium-sensing GPCR (CaSR) belongs to the
C family of the G-protein-coupled receptors GPCR, expressed
primarily, but not exclusively, in parathyroid glands and kidney
[1,2]. The CaSR senses changes in extracellular calcium
concentrations and regulates parathyroid hormone (PTH) secre-
tion and renal tubular calcium reabsorption to maintain serum
calcium levels within the normal range [3,4,5,6,7].
Ligand binding by the CaSR results in conformational changes
of the intracellular loops, G protein-dependent stimulation of
phospholipase C causing an accumulation of inositol 1,4,5-
trisphosphate and rapid release of calcium ions from intracellular
stores. The increase in intracellular calcium results in activation of
protein kinase C and CaSR also activates the mitogen-activated
protein kinase (MAPK) pathway [2,8].
Mutations in CaSR coding gene have been associated with
human diseases [9]. Loss-of-function CaSR mutations result in
familial (benign) hypocalciuric hypercalcemia (FBHH), and
neonatal severe primary hyperparathyroidism (NSHPT), charac-
terized by resistance to the normal inhibition of PTH secretion by
the hormone agonist, extracellular calcium [10,11,12].
Conversely, CaSR gain-of-function mutations cause autosomal
dominant hypocalcemia (ADH) or type 5 Bartter syndrome, due to
activation of the receptor at concentrations of serum calcium
below physiological levels leading to abnormal inhibition of PTH
secretion [13,14,15]. ADH patients display low serum calcium,
normal or low PTH levels, sometimes associated with hypercal-
ciuria and a Bartter-like syndrome, which predisposes those
patients to nephrocalcinosis [13,14,15]. Another serious compli-
cation associated with activating CaSR mutations is a defect in
bone mineralization [16] highlighting the importance of this
receptor in skeletal function as well [17]. So far, more than 50
activating mutations of the CaSR have been identified to cause
ADH (http://www.casrdb.mcgill.ca).
Similar to patients with ADH, mouse models for an activating
CaSR mutation display hypocalcemia, hyperphosphatemia and
inappropriately reduced levels of plasma PTH [18]. Transient
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expression of wild-type and mutant CaSRs in human embryonic
kidney (HEK) cells demonstrated that the mutation resulted in a
gain-of-function of the CaSR, which had a significantly lower
EC50 (‘left shift’) [19,20]. In addition to the activating mutation
causing ADH it has been reported that R990G polymorphism of
the CaSR also results in a gain-of-function of the receptor and
increased susceptibility to primary hypercalciuria [19,21].
Hypocalcemia in ADH patients is frequently treated with
calcium and vitamin D; however, this treatment can lead to
exacerbation of hypercalciuria, resulting in nephrocalcinosis,
nephrolithiasis and chronic renal failure [10,22]. Alternatively,
calcilytics which lower the sensitivity of the CaSR to external
calcium might offer a novel treatment option in patients with
ADH, although it is not known whether calcilytics would be
effective on mutated CaSR in ADH patients [23].
Clearly the best therapy for these diseases would be to directly
correct the underlining molecular defect of the receptor. However,
besides the reported increased sensitivity of the CaSR to external
calcium leading to lower Ca-EC50, little is known about the
molecular basis of gain-of-function variants of the CaSR.
Stimulation of CaSR elicits calcium mobilization from intra-
cellular stores rather then extracellular calcium influx [24]. To
understand the mechanism of CaSR mediating signaling and its
alterations in gain-of-function CaSR expressing cells, is therefore
essential to study the dynamics of intracellular calcium mobiliza-
tion ranging from transient and oscillatory responses to sustained
responses.
On the other hand, to maintain organellar calcium stores and
the appropriate concentration gradients across cell membranes,
mammalian tissues employ a large number of calcium-transport-
ing ATPases belonging to three subfamilies of the P-type
superfamily of ion-transport ATPases. These are the Secretory
Pathway Calcium-ATPases (SPCAs) [25], the Sarco-Endoplasmic
Calcium-ATPases (SERCAs) [26] and the Plasma Membrane
Calcium-ATPases (PMCAs) [27]. Together, these pumps establish
and maintain the calcium gradients that are essential for
physiological processes in which calcium plays a prominent role.
While the functions of the mammalian SPCA isoforms are not well
understood it is clear that SERCAs and PMCAs play major roles
in calcium signaling [28].
We report here that a complex parallel adaptive feedback can
explain the molecular basis of gain-of-function variants of the
CaSR. This involves a tight control of cytosolic and ER calcium
levels and parallel regulation of SERCA expression in the ER and
of PMCA at the plasma membrane.
Results
Expression and Localization of CaSR in HEK-293 Cells
HEK-293 cells were transiently transfected with vectors
encoding for the fused CaSRs with GFP, as described in Methods.
Confocal analysis revealed that hCaSR-wt as well as its gain-of-
function variants, hCaSR-R990G [19,29] and hCaSR-N124K
[20], were mainly expressed at the plasma membrane displaying
comparable expression efficiency in HEK-293 cells. In contrast,
hCaSR-D121, corresponding to a loss-of-function truncated
protein [30], localized intracellularly (Fig. 1A). By immunoblot-
ting, a monoclonal antibody recognizing the extracellular N-
terminus of CaSR (amino-acids 19–29) stained a band at
approximately 135 kDa and an aggregate at higher molecular
weight in lysates isolated from rat parathyroids and rat kidneys
(Fig. 1B). In a membrane-enriched fraction (17,0006g pellet) of
transfected cells specific bands corresponding to hCaSR-wt,
hCaSR-R990G and hCaSR-N124K were detected approximately
at 170 kDa. The higher molecular weight observed with respect to
native tissues is due to the presence of the GFP tag. In addition,
higher molecular mass forms, presumably dimers, were seen for all
receptor wild type and gain-of-function variants. The exogenous
expression of the truncated non-functional hCaSR-D121 protein
was detected only in the intracellular enriched fraction (200,0006g
pellet) consistent with prominent intracellular distribution (Fig. 1B).
To confirm the specificity of the revealed bands, cell extracts
from cells transiently transfected with hCaSR-wt, hCaSR-R990G
and hCaSR-N124K were probed with anti-GFP antibody. Anti-
GFP antibody stained bands at the same molecular weight as those
revealed by anti CaSR antibody thus confirming the specific
expression of CaSR variants in HEK-293 cells (Fig. 1C).
Figure 1. Expression and localization of Calcium Sensing
Receptors (CaSR) in HEK-293 cells. (A) Confocal microscopy
showing cellular localization of hCaSR-wt and the gain-of-function
variants hCaSR-R990G and hCaSR-N124K. hCaSR-wt as well as its active
variants, were mainly expressed at the plasma membrane. In contrast,
hCaSR-D121, corresponding to a loss-of-function truncated protein,
localized intracellularly. The scale bar corresponds to 5 mm. (B) Western
blotting analysis. Equal amounts of proteins (60 mg) isolated from tissue
lysates (parathyroid and rat kidney) or from cell 17,0006g pellet were
immunoblotted and probed with monoclonal antibodies against CaSR
(N-terminal, 1:800). In lysates isolated from rat parathyroid and rat
kidneys a band at approximately 135 kDa and an aggregate at higher
molecular weight was stained. An immunoreactive band of<170 kDa, a
band greater than 220 kDa marker and likely corresponding to higher
molecular mass forms of the receptor were detected only in cells
transfected with hCaSR-wt, hCaSR-R990G and hCaSR-N124K. The higher
molecular weight observed with respect to native tissues is due to the
presence of the GFP tag. In cells transfected with hCaSR-D121, the
antibody stained bands at approximately 40 kDa in a 200,0006g pellet
consistent with a prominent intracellular distribution. (C) Cell extracts
from cells transfected with hCaSR-wt, hCaSR-R990G, hCaSR-N124K and
hCaSR-D121 were immunoblotted and probed with a monoclonal anti-
GFP antibody (1:5000). Anti-GFP antibody stained bands at the same
molecular weight as those revealed by anti CaSR antibody confirming
the specificity of the revealed bands.
doi:10.1371/journal.pone.0079113.g001
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Signaling of Wild Type and Mutant Receptors
HEK-293 cells were transiently transfected with hCaSR-wt,
hCaSR-R990G, hCaSR-N124K and hCaSR-D121 and CaSR-
stimulated changes in intracellular calcium were measured. Cells
were loaded with Fura-2AM (4 mM), exposed to 2 mM, 4 mM
and 6 mM extracellular calcium and variations in intracellular
calcium (Ca2+i) were evaluated by single-cell epifluorescence
imaging and quantified with respect to basal levels (100%)
measuring the maximal change in DF/F0 (F0 is defined by the
average of fluorescent intensity at the basal level, whereas DF
equals to F1-F0). Figure 2 shows representative time course of
fluorescence responses of the wild type and mutant receptors. The
HEK-293 cells transfected with hCaSR-wt had a threshold
response to extracellular calcium levels of about 2 mM. Activation
of hCaSR-wt receptor induced typical calcium oscillations [31] in
response to extracellular calcium levels [Ca2+]o between 2 mM
and 4 mM, while the maximal response of the hCaSR-wt
characterized by a sustained intracellular calcium increase, was
observed between 5 mM and 6 mM (Fig. 2A; n= 51 cells). In
contrast, hCaSR-R990G exhibited a sustained intracellular
calcium increase already at 2 mM [Ca2+]o consistent with a
functional expression of a gain-of-function receptor (Fig. 2B;
n = 63 cells). Similarly, hCaSR-N124K showed a greater sensitiv-
ity to [Ca2+]o displaying calcium oscillations at 2 mM and a
sustained intracellular calcium increase starting from 4 mM
[Ca2+]o (Fig. 2C; n = 56 cells). No changes in intracellular calcium
levels were detected in cells expressing the truncated inactive
hCaSR-D121 (Fig. 2D; n= 38 cells) and in mock cells (n = 70 cells).
Calculation of the EC50 values obtained by normalization to the
maximal response of the wild type receptor, revealed that,
compared with hCaSR-wt, both the hCaSR-R990G and the
hCaSR-N124K mutant receptors showing a left shifted dose-
response curve had significant (P,0.0001) reduced EC50 values
(Fig. 2E).
For a more specific functional analysis of wild type and mutant
receptors, cells were treated with NPS-R, the allosteric CaSR
modulator that increases the sensitivity of the receptor for calcium.
A significant increase in intracellular calcium was observed in cells
expressing hCaSR-wt (Fig. 3A; n= 27 cells; 112.467.05%;
*P,0.0001) and its activating variants (Fig. 3B, n= 20 cells,
147.0613.02%, *P,0.0001; Fig. 3C, n= 21 cells, 141.6613.08%,
*P,0.0001) respect to mock (n= 33 cells; 22.3361.86%). No
response was observed in hCaSR-D121 expressing cells (Fig. 3D;
n= 25 cells). NPS-S, the much less potent NPS-R enantiomer, was
ineffective in all experimental conditions confirming the high
specificity of NPS-R effect (Fig. 3A–D). Interestingly, statistical
analysis of the fluorescence responses revealed that, compared to
the wild type, the activation of two gain-of-function receptors
resulted in a significant higher increase in fluorescence response
reflecting concomitant significant higher increase in intracellular
calcium in response to NPS-R (Fig. 3E).
Baseline Intracellular Calcium Measurements in Cells
Expressing CaSR Variants
Intracellular calcium level is strictly controlled to prevent over-
activation of cellular responses and the consequent cytotoxicity
due to prolonged exposure to high cytosolic calcium. Therefore,
the calcium gradient between cytosol and endoplasmic reticulum
(ER) is fundamental for correct transmission of transduction
signals.
We therefore analyzed whether expression of CaSR alters the
basal cytosolic calcium. At steady state, cells expressing hCaSR-wt
and its gain-of-function variants showed a significant decrease in
cytosolic calcium levels compared with mock and hCaSR-D121
expressing cells (intracellular calcium concentrations in transfected
cells: hCaSR-wt: 33.4462.39 nM; hCaSR-R990G:
31.6761.82 nM; hCaSR-N124K: 44.4561.89 nM; mock:
98.9664.32 nM; hCaSR-D121: 93.5867.01 nM, *P,0.0001)
(Fig. 4). These interesting data indicate that CaSR expression
results in modulation of unknown signaling components leading to
a significant reduction in intracellular calcium at rest. This is
expected to increase cell sensitivity to extracellular signals acting
through calcium signaling.
A counterpart measure to increase cell sensitivity to extracellular
signals in terms of intracellular calcium release would be to raise
the concentration of calcium stored in the ER. This is also
expected to increase the ER to cytosol gradient likely resulting in a
more pronounced cellular response to CaSR activators.
In line with this concept, we observed that the bulk of the ER-
released calcium was significantly higher in cells expressing
hCaSR-wt (12869.8 nM) and the activating variants (hCaSR-
R990G: 189.2615.24 nM; hCaSR-N124K: 156.5615.52 nM)
compared with mock (50.7861.85 nM, *P,0.0001) or cells
expressing hCaSR-D121 (82.9963.95 nM) (Fig. 5). The experi-
mental strategy employed to test this aspect was to treat cells with
ionomycin in the absence of Ca2+o [32] (see Methods for details).
Under such conditions, ionomycin caused Ca2+ release from
intracellular stores, resulting in a detectable rise in cytosolic
calcium levels. Of note, both activating CaSR variants were able
to promote significantly higher calcium release from the ER than
hCaSR-wt expressing cells (hCaSR-R990G vs hCaSR-wt,
#P,0.0001; hCaSR-N124K vs hCaSR-wt, $P,0.01). Indeed,
the hCaSR-R990G receptor variant apparently was significantly
more efficient at releasing calcium from the ER (hCaSR-R990G
vs hCaSR-N124K, &P,0.01).
The next step was to evaluate the actual calcium concentration
in the ER. To this end, we performed FRET experiments using
the ER-targeted Cameleon (D1ER) probe [33] containing a ER-
retention motif, which detects [Ca2+]ER directly. A scheme of
D1ER is shown in Figure 6A: when calcium binds to the
calmodulin motif (D1), it causes an intramolecular rearrangement
of the probe which leads to energy transfer between the donor and
acceptor molecules, resulting in FRET signal output.
Interestingly, we found that cells expressing the gain-of-function
CaSR variants, hCaSR-R990G (112.462.04% vs hCaSR-wt
10061.78%, **P,0.001) and hCaSR-N124K (109.661.84% vs
hCaSR-wt 10061.78%, *P,0.01), had a significantly higher
calcium concentration in the ER (Fig. 6B). Representative cells
expressing CaSR and its variants are indicated in the lower panel
where the FRET ratio is depicted in pseudocolor (Fig. 6C).
The efficiency of calcium accumulation in the ER is strictly
dependent on SERCA activity. Therefore, the next step was to
evaluate the expression and the activity of SERCA by immuno-
blotting and dynamic FRET respectively. Cells were lysed and
equal amount of proteins (60 mg) were immunoblotted and probed
with goat polyclonal antibody against SERCA2 (Fig. 7A). Statis-
tical analysis revealed that SERCA expression was significantly
higher in cells expressing activating CaSR variants (hCaSR-
R990G: 2.6960.79; hCaSR-N124K: 3.2760.67) compared to
mock (0.6960.25, *P,0.01), hCaSR-wt (0.7260.33, *P,0.01)
and hCaSR-D121 (0.6360.20, *P,0.01) expressing cells (Fig. 7B).
Of note, dynamic FRET revealed that the increase in SERCA
abundance is accompanied by a parallel increase in its activity.
The experimental strategy was to deplete calcium from the ER
using cyclopiazonic acid (CPA) and to measure the speed of
calcium re-uptake into the ER using a FRET-based D1ER sensor
(Fig. 7C). hCaSR-R990G and hCaSR-N124K expressing cells
showed a significant increased ability to accumulate calcium in the
Gain-of-Function Variants of the CaSR
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ER via SERCA respect to hCaSR-wt (*P,0.0001), as indicated by
the quantification of the initial slope of the FRET ratio (mock:
0.0660.006; hCaSR-wt: 0.0660.005; hCaSR-R990G:
0.13860.008; hCaSR-N124K: 0.09460.004; hCaSR-D121:
0.0560.006 ratio/min, Fig. 7C–D). Indeed, hCaSR-R990G
expressing cells displayed significantly higher SERCA activity
compared to the hCaSR-N124K variant (#P,0.0001).
The emerging picture is that a key point in regulating the
efficiency of CaSR signaling is to increase the ER to cytosol
gradient. For this, cells appear to monitor cytosolic and ER Ca2+
levels by modulating the expression of key signaling proteins. We
next evaluated whether cells also adjust the expression of the
PMCA pump and calbindin in order to stabilize the system.
Cell lysates (60 mg) were subjected to immunoblotting and
probed with specific antibodies recognizing PMCA1/4 (Fig. 8A).
Results revealed that the expression level of PMCA was
significantly reduced in hCaSR-R990G (0.16660.02) and
hCaSR-N124K (0.21960.03) cells (Fig. 8B) compared to that
observed in mock (0.82360.22, *P,0.01), hCaSR-wt
(0.67060.09, *P,0.01) and hCaSR-D121 (0.58860.14,
*P,0.01) expressing cells. These results are in agreement with
the comparable reduction in baseline calcium concentration
measured in hCaSR-wt, hCaSR-R990G and hCaSR-N124K
expressing cells. A reduction in PMCA expression observed only in
activating CaSR variants expressing cells might explain why those
cells, at rest, display similar calcium concentrations compared with
hCaSR-wt expressing cells.
No significant changes in the protein abundance of calbindin
were detected (Fig. 8C–D).
Discussion
In this study, we demonstrated for the first time that functional
expression of gain-of-function variants of the GPCR CaSR results
in parallel modulation of the expression level and activity of an
integrated set of regulatory proteins contributing to an excessive
signal transduction of mutant receptors.
Specifically the main findings reported in this work are
summarized as follows: (i) both the hCaSR-R990G and the
hCaSR-N124K mutant receptors had significant reduced EC50
values when compared with hCaSR-wt, (ii) basal intracellular
calcium concentration was significantly lower in cells expressing
hCaSR-wt and its activating variants compared to mock or loss-of-
function hCaSR-D121 expressing cells, (iii) FRET experiments
with the D1ER probe, which detects [Ca2+]ER directly, demon-
strated a significantly higher calcium accumulation in the ER in
cells expressing the activating CaSR variants compared to hCaSR-
wt expressing cells, (iv) SERCA expression and activity increased
significantly in cells expressing activating CaSR variants compared
to hCaSR-wt expressing cells. An inverse correlation with PMCA
was also found.
All these findings demonstrate that cells ‘sense’ expression of the
CaSR and adopt multiple parallel adaptive regulatory mechanisms
aimed at controlling the expression levels of crucial regulatory
Figure 2. Effects of increasing concentration of extracellular calcium on [Ca2+]i levels. Cells transiently transfected with (A) hCaSR-wt, (B)
hCaSR-R990G, (C) hCaSR-N124K and (D) hCaSR-D121 were stimulated with increasing levels of [Ca2+]o and fluorescence ratio 340 nm/380 nm was
recorded and calculated as the change in fluorescence (DF/F0), normalized to basal fluorescence ratio observed in the absence of stimulus (100%).
Each trace is representative of 3–4 different experiments with similar results. (E) Calculated EC50 for hCaSR-wt, hCaSR-R990G and hCaSR-N124K.
doi:10.1371/journal.pone.0079113.g002
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proteins involved in calcium homeostasis. This combined
integrated protein regulation on the one hand contributes to
lowering resting intracellular calcium concentration and on the
other increases calcium accumulation in the ER.
Stabilization of basal cytosolic calcium to low levels (50 nM
range) and the differential higher accumulation of calcium in the
ER due to higher SERCA activity in cells expressing CaSR
activating variants, are predicted to render cells more sensitive to
extracellular CaSR agonists. Of note we found that cells adjust the
expression levels of PMCA on the plasma membrane, which was
reduced in cells expressing the gain-of-function CaSR variants.
This likely implies that comparable levels of intracellular resting
calcium are reached either in cells expressing hCaSR-wt or
activating CaSR variants. While non-selective plasma membrane
calcium channels could also contribute to the low basal level of
cytosolic calcium observed in cells expressing functional CaSR
variants, our findings point to SERCA and PMCA as two
candidate transporters involved in this effect.
Altogether, our data provide significant new knowledge to help
explain the molecular basis of gain-of-function variants of the
calcium-sensing receptor (CaSR). In fact, while previous studies
showed that the functional consequence of expressing gain-of-
function mutations of the CaSR is basically higher sensitivity to
external calcium as assessed by reduced EC50 values for external
calcium [23], the present contribution indicates that variations in
key protein expression explain how the calcium signaling system is
affected (and exacerbated) by activating CaSR variants.
Figure 3. Effects of the calcymimetic NPS-R and its inactive form NPS-S on [Ca2+]i. Cells transiently transfected with (A) hCaSR-wt, (B)
hCaSR-R990G, (C) hCaSR-N124K and (D) hCaSR-D121 were stimulated with NPS-R (5 mM) and NPS-S (5 mM). Fluorescence ratio 340 nm/380 nm was
recorded and responses to NPS-R were calculated as the change in fluorescence (DF/F0), normalized to basal fluorescence ratio observed in the
absence of stimulus (100%). Each trace is representative of 3 different experiments with similar results. (E). Histogram showing the DF/F0. Data are
expressed as means 6 SE. (*P,0.0001 vs mock; #P,0.001 vs hCaSR-wt).
doi:10.1371/journal.pone.0079113.g003
Gain-of-Function Variants of the CaSR
PLOS ONE | www.plosone.org 5 November 2013 | Volume 8 | Issue 11 | e79113
As previously discussed, the gain-of-function CaSR mutations
result in autosomal dominant hypocalcemia (ADH) or type 5
Bartter syndrome and eight of them are clustered in loop 2
close to the two cysteines responsible for receptor homodimer-
ization, i.e. cys 129 and cys 131 [34]. The missense mutation
N124K analyzed in this work is located in the CaSR
extracellular domain in loop 2 and this substitution has been
previously shown to cause an increase in sensitivity to external
calcium rather than cause constitutive activation [20]. Based on
the three-dimensional structure of related metabotropic gluta-
mate type 1 receptor, it has been speculated that the N124K
mutation of CaSR changes the receptor structure, decreasing
the normal constraints to rotation of the dimer [20]. On the
other hand, a gain-of-function effect is also observed in
autoimmune polyglandular syndrome type 1, in which autoan-
tibodies bind the N-terminus of the CaSR stabilizing activating
conformation of the receptor [35].
While the N124K CaSR mutations causing ADH in humans is
located in the extracellular domain, the intracellular tail of the
receptor has one non-conservative polymorphism, R990G, which
also confers a gain-of-function to the receptor (lower external
calcium EC50) and in humans is associated with primary
hypercalciuria in patients [19,21,36].
Although the two gain-of-function CaSR variants examined in
this work regard modifications at opposite locations within the
CaSR protein sequence, their functional analysis revealed
comparable biological regulatory effects within cells: a. signifi-
cantly higher calcium accumulation in the ER and SERCA
expression and activity, b. reduced expression of the PMCA,
which is perfectly in line with the comparable (low) basal cytosolic
calcium concentration found in cells expressing hCaSR-wt.
These results likely reflect the need to preserve optimal
intracellular calcium concentrations, while assuring differential
responses for hCaSR-wt or activating CaSR variants. In fact,
the observed significant higher activity of the SERCA pump
might cause a dangerous drop in basal cytosolic calcium which
can disrupt the normal activities of calcium dependent
proteases, phosphatases and other effectors [37]. To avoid that,
the selective downregulation of PMCA observed in activating
CaSR variant expressing cells (Fig. 8) represents a very efficient
feedback regulation in order to stabilize the system. The
relevance of the SERCA-PMCA interplay in maintaining the
calcium gradient across cellular membranes is also confirmed by
previous studies in SERCA and PMCA knockout mice [28].
Moreover prolonged stimulation of the CaSR signaling might
modulate gene expression contributing to modify cellular
phenotype [38,39].
The emerging picture here is that cells respond to the
functional expression of the CaSR activating variants with a
series of adaptive mechanisms. Our data point to the concept
that multiple parallel adaptive feedback loops ‘sense’ ectopic
expression of the CaSR variants by altering ER and cytosolic
calcium concentrations and adjusting the expression levels of
SERCA and PMCA for efficient signaling. In this scenario,
Ca2+ plays an important role in controlling the expression
patterns of calcium regulated players that are differentially
modulated in both health and disease [40].
Given the complexity of feedbacks in the calcium signaling
system analyzed in this work, it is clearly difficult to understand the
mechanisms behind these parallel adaptive regulations of protein
expression and activity. Clues in this direction come from an
elegant recent work by Gong and coworkers, demonstrating that
activation of the CaSR regulates the expression levels of two
microRNAs: miR-9 and miR-374, which in turn transduce the
extracellular signal to CLDN14 through microRNA mediated
gene silencing [41]. Although, this study reported miR-9 and miR-
374 convergence onto CLDN14, regulation of microRNA by
CaSR signaling may occur on several layers including key
regulatory proteins involved in CaSR receptor activated calcium
signaling.
In conclusion, our findings identify a unique adaptive principle
in the calcium signaling system associated with activating variants
of the CaSR whereby SERCA, PMCA and possibly other
signaling components are regulated by multiple expression
feedbacks so that modifications in ER and cytosolic calcium levels
are paralleled by modified concentrations of key signaling pathway
components. This combined parallel regulation in protein
expression increases the ER to cytosol calcium gradient explaining
the higher sensitivity of CaSR gain-of-function variants to external
calcium.
Figure 4. Effect of expression of hCaSR-wt and its variants on
free cytosolic [Ca2+] at steady state. HEK-293 cells were transiently
transfected and the free cytosolic [Ca2+] was calculated 48–72 hours
after transfection accordingly to Grynkiewicz formula [32], as described
in Methods. Cytosolic calcium was measured in mock cells (n = 114
cells), hCaSR-wt (n = 64 cells), hCaSR-R990G (n = 89 cells), hCaSR-N124K
(n = 72 cells) and hCaSR-D121 (n = 96 cells). Data are expressed as
means 6 SE. (*P,0.0001 vs mock or hCaSR-D121).
doi:10.1371/journal.pone.0079113.g004
Figure 5. Effect of expression of hCaSR-wt and its variants on
calcium release from the internal stores. HEK-293 cells were
transiently transfected as described in Methods and the experiments
were executed 48–72 hours after transfection. The calcium released by
the internal stores was calibrated by adding ionomycin (5 mM) in the
absence of Ca2+o, according to the Grynkiewicz formula [32].
Measurements were performed in mock cells (n = 69 cells), hCaSR-wt
(n = 46 cells), hCaSR-R990G (n = 49 cells), hCaSR-N124K (n = 48 cells) and
hCaSR-D121 (n = 56 cells). Data are expressed as means 6 SE.
(*P,0.0001 vs mock; #P,0.0001 hCaSR-R990G vs hCaSR-wt;
$P,0.001 hCaSR-N124K vs hCaSR-wt; &P,0.01 hCaSR-R990G vs
hCaSR-N124K).
doi:10.1371/journal.pone.0079113.g005
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Figure 6. Evaluation of [Ca2+]ER with ER-targeted cameleon (D1ER) probe. Schematic model of the cameleon (D1ER) probe showing
calreticulin signaling sequence flanked by the ECFP, calcium binding calmodulin domain (D1) and citrine to monitor the ER-calcium stored. Binding of
calcium to calmodulin sequence results in an intramolecular rearrangement of the probe consistently with an increase in FRET signal. (B) Histogram
compares changes in nFRET among mock cells (n = 98 cells), hCaSR-wt (n = 75 cells), hCaSR-R990G (n = 98 cells), hCaSR-N124K (n = 77 cells) and
hCaSR-D121 (n = 75 cells). Data are expressed as means 6 SE. (**P,0.001; *P,0.01). (C) The FRET signal (ratio of 530/470 nm) is depicted in
pseudocolor. The scale bar corresponds to 5 mm.
doi:10.1371/journal.pone.0079113.g006
Figure 7. Evaluation of SERCA expression and activity. Western blotting analysis. Equal amount of proteins (60 mg) from cell lysates were
immunoblotted and probed with goat polyclonal antibody against SERCA2 (recognizing both the a and b isoforms; 1:500). (B) Densitometry of the
immunoreactive bands. Statistical analysis revealed that the SERCA2 expression, normalized against GAPDH, was significantly higher in cells
expressing activating CaSR variants (data expressed as means6 SE; *P,0.01 vs mock or hCaSR-wt). (C) Dynamic FRET. Calcium was depleted from the
ER and the speed of calcium re-uptake into the ER was measured with a FRET-based D1ER sensor. (D) Statistical analysis of the SERCA evaluated based
on the initial slope of the ratio increase after calcium readdition. Data are expressed as means 6 SE. (*P,0.0001 vs hCaSR-wt; #P,0.0001 hCaSR-
R990G vs hCaSR-N124K).
doi:10.1371/journal.pone.0079113.g007
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Materials and Methods
Materials
All chemicals were purchased from Sigma (Sigma-Aldrich,
Milan, Italy). Fura-2AM was obtained from Molecular Probes
(Life Technologies, Monza, Italy). NPS-R568 and the enantiomer
NPS-S568 were kindly gifted by Amgen (Amgen Dompe´ S.p.a.,
Milan, Italy).
Antibodies
Monoclonal CaSR antibody recognizing amino-acid 15–29 at
the extracellular N-terminus [42,43] was from Sigma-Aldrich,
Milan, Italy. Calbindin-28K antibody was purchased from Sigma
whereas PMCA1/4 and SERCA2 (N-19 recognizing both the a
and b isoform) antibodies were obtained from Santa Cruz
Biotechnologies (Tebu Bio, Milan, Italy). Monoclonal antibody
against Green Fluorescent Protein (GFP) was from Covance
(Emeryville, CA, USA). Monoclonal antibody against Glyceralde-
hyde-3-Phosphate Dehydrogenase (GAPDH, clone 6C5) was
purchased from Millipore (Millipore Corporation, USA).
DNA Constructs
For generation of the PCR3.1 constructs encoding for human
CaSR wild-type (hCaSR-wt) and its variants (hCaSR-R990G;
hCaSR-N124K; hCaSR-D121, the coding sequences were ampli-
fied by PCR and subcloned in frame in pAC-GFP1-N1. The
obtained GFP-fused mutants are functional and correctly targeted
to the plasma membrane. The presence of the GFP tag does not
alter CaSR function and trafficking as previously described [44].
Cell Culture and Transfection
Human embryonic kidney (HEK-293) cells, were grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose,
GlutaMAXTM, pyruvate, supplemented with 10% (v/v) fetal
bovine serum and 100 i.u./ml penicillin, 100 mg/ml streptomycin
at 37uC in 5% CO2. HEK-293 cells were seeded on a poly-L-
lysine hydrobromide substrate and grown for 24 h at 80%
confluence.
Cells were transiently transfected with plasmids (0.4 mg of
DNA/cm2) encoding for hCaSR-wt and its variants fused with the
green fluorescent protein (GFP), using lipofectamine (1 mg/ml)
according to the protocol provided by the manufacturer (Life
Technologies, Monza Italy). Experiments were performed 48–72
hours post-transfection.
Cell Preparations
HEK-293 cells were lysed in RIPA Buffer (150 mM NaCl,
10 mM Tris, pH 7.2, 0.1% SDS, 1.0% Triton X-100, 1%
Deoxycholate, 5 mM EDTA) in the presence of proteases
(1 mM PMSF, 2 mg/ml leupeptin and 2 mg/ml pepstatin A)
and phosphatases (10 mM NaF and 1 mM sodium orthovanadate)
inhibitors. Cellular debris was removed by centrifugation at
12,0006g for 20 min at 4uC. The supernatants were collected and
used for immunoblotting studies. Alternatively, cells were scraped
and sonicated in a buffer containing 220 mM mannitol, 70 mM
sucrose, 20 mM Tris-HCl in the presence of protease and
phosphatase inhibitors. Nuclei and mitochondria enriched frac-
tions were removed by centrifugation at 8006g and 80006g
respectively for 20 minutes at 4uC. Membrane enriched fractions
were obtained by centrifugation for 1 hour at 4uC at 17,0006g in
Figure 8. PMCA and Calbindin expression. (A) Western blotting analysis of PMCA. Fractions enriched in plasma membrane were prepared and
equal amounts of proteins (60 mg) from each cell line were subjected to Western Blotting analysis with anti-PMCA (1:300) and revealed with anti-
mouse HRP-coupled secondary antibodies. (B) Statistical analysis of the detected bands. PMCA abundance was significantly reduced in cells
expressing activating CaSR variants (means 6 SE; *P,0.01 vs hCaSR-wt or mock). (C) Western blotting analysis of Calbindin. Equal amounts of
proteins (60 mg) from cell lysates were immunoblotted, probed with monoclonal antibodies against calbindin (N-terminal, 1:2000) and revealed with
anti-mouse HRP-coupled secondary antibodies. (D) Densitometric analysis of the revealed bands. No significant change in calbindin abundance was
observed in cells expressing hCaSR-wt or its activating and inactivating variants.
doi:10.1371/journal.pone.0079113.g008
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a Beckman Allegra 64R centrifuge. The supernatants were spun at
200,0006g for 1 hour at 4uC.
Gel Electrophoresis and Immunoblotting
Cellular proteins were separated on 10% bis-tris acrylamide gels
under reducing conditions. Protein bands were electrophoretically
transferred onto Immobilon-P membranes (Millipore Corporate
Headquarters, Billerica, USA) for Western blot analysis, blocked in
TBS-Tween-20 containing 3% BSA and incubated with primary
antibodies O/N.
Immunoreactive bands were detected with secondary antibody
conjugated to horseradish peroxidase (HRP) obtained from Santa
Cruz Biotechnologies (Tebu Bio, Milan, Italy). Membranes were
developed using SuperSignal West Pico Chemiluminescent
Substrate (Pierce, Rockford, USA) with Chemidoc System (Bio-
Rad Laboratories, Milan, Italy). Band intensities were quantified
by densitometric analysis using National Institutes of Health (NIH)
ImageJ software.
CaSR Cellular Localization
HEK-293 cells were seeded onto Ø10 mm glass coverslips,
grown, transfected as described above, and fixed for 30 min with
4% paraformaldehyde in PBS. Following fixation, samples were
mounted on glass slides with Mowiol. Images were obtained with a
confocal microscope Leica TCS SP2 (Leica Microsystems,
Heerbrugg, Switzerland).
Functional Analysis of Wild-Type and Mutant Receptors.
Intracellular Calcium Measurements
For intracellular Ca2+ measurements, cells were grown on
Ø40 mm glass coverslips. HEK-293 cells were loaded with 4 mM
Fura-2AM for 20 min at 37uC in DMEM. Ringer’s Solution was
used to perfuse cells during the experiment containing 140 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 10 mM Hepes, 5 mM Glucose,
1.8 mM CaCl2, pH 7.4. In fluorescence measurements, the
coverslips with dye-loaded cells were mounted in a perfusion
chamber (FCS2 Closed Chamber System, BIOPTECHS, Butler,
U.S.A.) and measurements were performed using an inverted
microscope (Nikon Eclipse TE2000-S microscope) equipped for
single cell fluorescence measurements and imaging analysis. The
sample was illuminated through a 40X oil immersion objective
(NA=1.30). The Fura-2AM loaded sample was excited at 340 and
380 nm. Emitted fluorescence was passed through a dichroic
mirror, filtered at 510 nm (Omega Optical, Brattleboro, VT,
USA) and captured by a cooled CCD camera (CoolSNAP HQ,
Photometrics). Fluorescence measurements were carried out using
Metafluor software (Molecular Devices, MDS Analytical Tech-
nologies, Toronto, Canada). The ratio of fluorescence intensities at
340 and 380 nm was plotted and calculated as the change in
fluorescence (DF/F0), expressed as percentage of the basal
fluorescence ratio observed in the absence of stimulus.
The Ec50 shift was calculated by normalization to the maximal
response of the wild type receptor and obtained with Graph Prism
program.
For the experiments at steady state, intracellular calcium level
was calibrated and then calculated as described by Grynkiewicz
[32]. Briefly, calcium concentration was determined from the
emission fluorescence ratio of the two excitation wavelengths
accordingly to the formula [Ca2+]i =Kd*Q(R-Rmin)/(Rmax-R),
where Kd (224 nM) indicated the dissociation constant of Fura-
2AM for Cai and Q indicated the ratio of the fluorescence
intensities (F) at the minimum and the maximum calcium
concentration at 380 nm. Each sample was calibrated by the
addition of 5 mM ionomycin in presence of 1 mM EGTA (Rmin)
followed by 5 mM ionomycin in 5 mM CaCl2 (Rmax).
Fluorescence Resonance Energy Transfer (FRET)
Measurements
FRET experiments were performed as described [45]. Briefly,
HEK-293 cells were transiently co-transfected with plasmids
encoding CaSR-wt or its variants and D1ER cameleon, (gift from
Prof. Roger Tsien) [33], for FRET studies. FRET measurements
were carried out using MetaMorph software (Molecular Devices,
MDS Analytical Technologies, Toronto, Canada). ECFP and
citrine were excited at 435 or 509 nm, respectively. FRET from
ECFP to citrine was determined by excitation of ECFP and
measurement of fluorescence emitted from citrine. Corrected
nFRET values were determined accordingly to Tamma et al. [45].
Statistical Analysis
Data are reported as mean values 6 SEM. Statistical analysis
was performed by one-way ANOVA followed by Newman-Keuls
Multiple Comparison test with p,0.05 were considered statisti-
cally different.
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